zileuton Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
2862 111406-87-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zileuton
  • leutrol
  • A-64077
  • A 64077
an orally active inhibitor of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid
  • Molecular weight: 236.29
  • Formula: C11H12N2O2S
  • CLOGP: 2.48
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 66.56
  • ALOGS: -3.64
  • ROTB: 2

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 9, 1996 FDA CHIESI USA INC

FDA Adverse Event Reporting System

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
CHEBI has role CHEBI:49159 leukotriene antagonist
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drug
CHEBI has role CHEBI:49167 anti-asthmatic drug
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006727 Hormone Antagonists
MeSH PA D020024 Leukotriene Antagonists
MeSH PA D016859 Lipoxygenase Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
FDA EPC N0000175956 5-Lipoxygenase Inhibitor
FDA MoA N0000175955 5-Lipoxygenase Inhibitors
FDA PE N0000008683 Decreased Leukotriene Production

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Non-allergic asthma indication 266361008 DOID:9360
Allergic asthma indication 389145006 DOID:9415
Asthma management indication 406162001
Suicidal thoughts contraindication 6471006
Hallucinations contraindication 7011001
Mood swings contraindication 18963009
Feeling agitated contraindication 24199005
Depressive disorder contraindication 35489007
Anxiety contraindication 48694002
Dream disorder contraindication 85418005
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Tremors contraindication
Nervousness contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.96 acidic
pKa2 13.02 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Arachidonate 5-lipoxygenase Enzyme INHIBITOR IC50 6.52 CHEMBL CHEMBL
Arachidonate 5-lipoxygenase-activating protein Cytosolic other IC50 5.66 CHEMBL
Leukotriene B4 receptor 1 GPCR IC50 6.38 CHEMBL
Cysteinyl leukotriene receptor 2 GPCR IC50 5.82 WOMBAT-PK
Leukotriene A-4 hydrolase Enzyme IC50 6.07 WOMBAT-PK
Bifunctional epoxide hydrolase 2 Enzyme IC50 6.23 CHEMBL
Arachidonate 5-lipoxygenase Enzyme IC50 6.85 CHEMBL
Arachidonate 5-lipoxygenase Enzyme IC50 6.72 CHEMBL

External reference:

IDSource
4021009 VUID
N0000148478 NUI
C0081408 UMLSCUI
D00414 KEGG_DRUG
386180009 SNOMEDCT_US
4021009 VANDF
d04103 MMSL
5704 MMSL
40575 RXNORM
108617005 SNOMEDCT_US
006297 NDDF
254934 MMSL
60490 PUBCHEM_CID
CHEBI:10112 CHEBI
CHEMBL93 ChEMBL_ID
DB00744 DRUGBANK_ID
V1L22WVE2S UNII
6595 INN_ID
5297 IUPHAR_LIGAND_ID
C063449 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZYFLO HUMAN PRESCRIPTION DRUG LABEL 1 10122-901 TABLET 600 mg ORAL NDA 13 sections
Zileuton HUMAN PRESCRIPTION DRUG LABEL 1 49884-723 TABLET, MULTILAYER, EXTENDED RELEASE 600 mg ORAL ANDA 16 sections
Zileuton HUMAN PRESCRIPTION DRUG LABEL 1 64980-206 TABLET, EXTENDED RELEASE 600 mg ORAL ANDA 17 sections
Zileuton HUMAN PRESCRIPTION DRUG LABEL 1 66993-485 TABLET, EXTENDED RELEASE 600 mg ORAL NDA AUTHORIZED GENERIC 16 sections
ZILEUTON HUMAN PRESCRIPTION DRUG LABEL 1 68180-169 TABLET, EXTENDED RELEASE 600 1 ORAL ANDA 17 sections